We are live on ! Find out more
RDHL

Redhill Biopharma

22 hedge funds and large institutions have $24.9M invested in Redhill Biopharma in 2016 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

800% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 1

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

5% more funds holding

Funds holding: 2122 (+1)

0% more ownership

Funds ownership: 0%0% (+0%)

9% less capital invested

Capital invested by funds: $27.3M → $24.9M (-$2.39M)

Holders
22
Holders Change
+1
Holders Change %
+4.76%
% of All Funds
0.55%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
9
Reduced
1
Closed
3
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
FM
26
Family Management
New York
-$229K -17 Closed
WA
27
WFG Advisors
Texas
-$10K -1 Closed
AIM
28
Acrospire Investment Management
Illinois
-$6K
TRCT
29
Tower Research Capital (TRC)
New York
-$1K

RDHL Hedge Fund Activity: Q4 2016 in Review

22 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Redhill Biopharma (RDHL) for Q4 2016, worth a combined $24.9M — down 8.8% from $27.3M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new RDHL positions and 3 closed out — a net gain of 1 holder — while 9 added to existing stakes and 1 trimmed.

The largest buyer was Migdal Insurance & Financial Holdings, opening a new position worth an estimated $4.69M. The largest seller was Broadfin Capital, cutting an estimated $5.57M.

  • 22 institutional investors held Redhill Biopharma (RDHL) as of Q4 2016, up from 21 in Q3 2016.
  • Funds reported $24.9M of Redhill Biopharma stock for Q4 2016, down 8.8% quarter-over-quarter.
  • 4 funds opened new Redhill Biopharma positions in Q4 2016 and 3 closed out, a net change of +1 holder.
  • The largest Redhill Biopharma buyer in Q4 2016 was Migdal Insurance & Financial Holdings, an estimated $4.69M added.
  • The largest Redhill Biopharma seller in Q4 2016 was Broadfin Capital, an estimated $5.57M sold.

Based on aggregated 13F filings for Q4 2016.